No-Stress Stress Test Brings Relief to Heart Failure Patients

Apr 30, 2010 by Jeanne Galatzer-Levy

(PhysOrg.com) -- The University of Illinois Medical Center at Chicago is the first academic medical center in the country to introduce a new "no stress" diagnostic system for assessing patients with heart failure and optimizing their treatment.

A patient's heart efficiency is usually assessed using a that requires near peak performance.

"Heart failure patients are simply unable to undergo the kind of exertion a stress test requires," says Dr. Abraham Kocheril, UIC professor of medicine and director of clinical electrophysiology.

But with the Shape-HF Cardiopulmonary Testing System, the patient need only step up and down a 6-inch raised platform or walk a slow, steady, 1 mph on the treadmill -- exertion well within the capacity of most heart failure patients.

The patient breathes into a tube while exercising at a normal daily activity level. The breath passes through a small box where it is analyzed for the blood gases, and a computer shows the physician the results in real time.

In heart failure, a patient's heart is unable to pump effectively and cannot meet the body's need for blood and oxygen. More than 5.5 million Americans have heart failure, according to the American Heart Association, and 670,000 new cases are diagnosed each year.

Patients with tire easily, suffer from shortness of breath and are often unable to work. Implanted electronic medical devices that monitor heart rhythm and stimulate the heart when arrhythmias occur can be life-saving for many and dramatically improve their quality of life, making breathing easier and keeping them out of the hospital.

But 30 percent of patients do not respond to these implanted defibrillators and pacemakers, Kocheril said, and optimizing the settings of the devices has been a process of trial and error.

Queen Page, 66, of Chicago, came to UIC for the test using a scooter and a cane. After four heart attacks, she had had a cardiac re-synchronization therapy defibrillator implanted in 2006. Although she did well at first, she was set back by a car accident and was once again suffering from weakness and fatigue.

As she began her test, even walking on the treadmill at the very slow pace of 1 mph was difficult. But as Page walked, Kocheril optimized her defibrillator by making fine adjustments using readouts of her blood gases every two minutes.

"By the end of the test I felt good enough to go dancing!" Page said.

Today, Page walks to the bus stop, church, and everywhere she needs to go. No cane, no scooter. She rides her stationary bike three times a day for 15 minutes and has signed up for a step class at her local gym.

Kocheril also sees potential for the new diagnostic tool in a number of other cardiac conditions. Pulmonary arterial hypertension, for example, often presents non-specific symptoms and a combination of lung and heart problems. Current tests do not give the physician enough information to discern how to appropriately treat this mix of problems, Kocheril said.

"'Shape' will give us potentially more objective and directly relevant information, allowing a much more targeted medical approach," he said.

Kocheril worked with Shape Medical Systems, Inc., developer of Shape-HF, to produce an easy-to-understand report that can help referring physicians implement targeted treatments for their cardiac patients based on information from the test.

Explore further: Allergan to cut 1,500 employees in restructuring (Update)

add to favorites email to friend print save as pdf

Related Stories

New heart failure device is tested

Oct 17, 2006

Physicians at 50 U.S. medical facilities are taking part in a multinational clinical trial of a device designed to help heart failure victims.

New therapy found to prevent heart failure

Jun 23, 2009

A landmark study has successfully demonstrated a 29 percent reduction in heart failure or death in patients with heart disease who received an implanted cardiac resynchronization therapy device with defibrillator (CRT-D) ...

Compound Shows Promise Against Intractable Heart Failure

Feb 11, 2010

(PhysOrg.com) -- A chemical compound found normally in the blood has shown promise in treating and preventing an intractable form of heart failure in a mouse model of the disease, report researchers at the University of Illinois ...

Recommended for you

British Lords hold ten-hour debate on assisted dying

Jul 19, 2014

Members of Britain's unelected House of Lords spent almost ten hours on Friday discussing whether to legalise assisted dying, in an often emotional debate putting the question back on the agenda, if not on the statute books.

AbbVie, Shire agree on $55B combination

Jul 18, 2014

The drugmaker AbbVie has reached a deal worth roughly $55 billion to combine with British counterpart Shire and become the latest U.S. company to seek an overseas haven from tax rates back home.

Safety problems at US germ labs acknowledged

Jul 16, 2014

(AP)—The director of the U.S. Centers for Disease Control and Prevention acknowledged Wednesday that systemic safety problems have for years plagued federal public health laboratories that handle dangerous ...

User comments : 0